FREE Stock Alerts By Email!
Mail Comments To: lung disease , supplemental oxygen allows their bodies to get the
oxygen that they need and may also help them be more active.
To say that we need oxygen to exist is as obvious as saying we need water. But
as we all know, water can also be a destructive force. The key, of course, is having
the right amount in the right place at the right time. That is just as important for oxygen, especially for those who require supplementary oxygen.
An essential component to this remedy is a flow meter to ensure that the right
amount of oxygen is being delivered, and just as important that it is being
delivered at all. Regardless of the use of an oxymeter to measure blood gas, Oxyview ® provides vital information related to functionality of the cannula and all of the oxygen equipment. If something is wrong with the cannula or equipment, the Oxyview ® will show you immediately. This is usually achieved by a pneumatic flow meter, but most that are currently on the market are expensive, attach at the tank, and are gravity-operated, which means that they only work in the vertical position with or without the cannula attached at the delivery source. In contrast, Oxyview ® attaches to the cannula close to the patient— where oxygen matters the most. Oxyview ® is 97 percent accurate and works hands-free in any position, whereas the conventional flow meter is less than 80 percent accurate and does not attach to the cannula.
Gravity-operated devices are also inconvenient for the patient since they must
keep the tanks within sight to check the gauges for flow rate. If the tank is tilted
even slightly, the gravity-operated flow meter becomes even more inaccurate and may cease functioning because friction is too great. One alternative is a digital flow meter, but these may be prohibitively expensive.
That’s why the Oxyview ® flow meter ( Ingen Technologies, Inc.,
Yucaipa, CA ) is a significant advance in the technology. When first launched in
November 2007, it represented a new generation of pneumatic real-time safety devices. It has some notable features: accurate to within + 3% and versatile enough to work with all respiratory equipment—CP AP, concentrators, liquid and gas cylinders, on-demand conservers and more. It is not gravity-dependent and so can be placed at any point in the tubing, even by the patients themselves. Having the device close by for easy viewing allows the patient assurance and confidence, knowing that there is a flow of oxygen at the correct level. They are also able to quickly see if the regulator or concentrator is not working properly.
Current Projects
Ingen Brings Aboard Leading OEM Partner for Australia:
Ingen Technologies, Inc., recently announced that Medical Industries Australia has
signed an OEM contract with Ingen. Approximately 1,000 COPD patients, each day,
occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it`s due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis. Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services for more than 20 years.
Ingen Cuts Manufacturing Costs and Increases Its Margins:
Ingen Technologies, Inc. recently received a proposal from a leading manufacturer
to help reduce production costs and material costs by 50% for the manufacture of the
Oxyview and the Oxyview Nasal Cannula. Now that they are selling their respiratory products, and sales have escalated, they must reduce their cost of goods sold in order to increase their profit margins and decrease the costs to their dealers and buyers. This change will give the company a stronger foot-hold in the market. The company has a proprietary product and there is nothing in the marketplace that can compete with their device.
Comparables
· Lincare Holdings Inc.
(Lincare) is a provider of oxygen and other respiratory therapy services to patients
in the home. Lincare’s customers suffer from chronic obstructive pulmonary disease (COPD), such as emphysema, chronic bronchitis or asthma, and require supplemental oxygen or other respiratory therapy services in order to alleviate the symptoms and discomfort of respiratory dysfunction.. Lincare primarily provides oxygen and other respiratory therapy services to patients in the home. NASDAQ:LNCR Recent Price: $31.41
· American Homepatient,
Inc. provides home healthcare services and products consisting primarily of
respiratory therapy services, home infusion therapy services, and the rental and sale of home medical equipment and home health care supplies. The Company’s services and products are paid for primarily by Medicare, Medicaid, and other third-party payors. OTCBB:AHOM Recent Price: $.230
Good luck and happy hunting ! - Dave Reiner
Disclaimer
Microcap Alliance discloses to the readers of this information that
it was compensated five thousand dollars for consluting services and
coverage of Ingen Technologies, Inc. in this newsletter. Microcap Alliance, Inc. or its officers may buy or hold, has sold, is selling and will sell common shares of mentioned companies, in the open market or in private transactions at any time without notice. Microcap Alliance, Inc.`s services for a company may cause the company`s stock price to increase, and thus Microcap Alliance, Inc. would make a profit when it sells its stock in a company. Also, Microcap Alliance,Inc.` s selling of a company`s stock may have a negative effect on the market price of the stock.
Through use of this information, you agree to hold Microcap Alliance, Inc., its
operators owners and employees harmless and to completely release them from any and
all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please read our full disclaimer: http://www.microcapalliance.com/disclaimer
See Microcap Alliance's website for full disclaimer. Microcap Alliance may have received compensation for stock picks.
home
